February 23, 2017
Prepubertal and adolescent children with Prader-Willi syndrome treated with recombinant human growth hormone therapy before the onset of puberty saw increased linear growth and adult height over at least 3 years of treatment, according to a worldwide, retrospective cohort study.
“Long-term data of a large group of GH-treated prepubertal children with [Prader-Willi syndrome] have not been reported,” N.E. Bakker, MD, of the Dutch Growth Research Foundation in Rotterdam, the Netherlands, and colleagues wrote. “Results of nationwide studies from the USA, the Netherlands and Switzerland are reassuring, but have the limitation of small patient numbers because [Prader-Willi syndrome] is a rare syndrome. Therefore, the present study was undertaken to evaluate growth during 3 years of GH treatment and adult height data in a large group of children with [Prader-Willi syndrome], by using the Pfizer International Growth Database (KIGS), containing data from 1987 to 2012.”